Dr. Matthias Holdhoff is a medical oncologist and co-director of the Brain Cancer Disease Group at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is a professor of oncology, neurology and neurological surgery at Johns Hopkins University School of Medicine. Dr. Holdhoff’s expertise is in primary brain cancers and central nervous system lymphomas. He earned his medical degree from Freie Universität Berlin, received his doctorate degree at Charité University Medicine Berlin. Dr. Holdhoff completed residency training in internal medicine at Johns Hopkins Bayview Medical Center, followed by a fellowship in medical oncology at Johns Hopkins Hospital with research training at the Ludwig Center for Cancer Genetics and Therapeutics (Kinzler-Vogelstein lab). As a clinical investigator in neuro-oncology, his research is focused on novel trials and translational biomarker studies in malignant gliomas and primary central nervous system lymphomas. He has led and contributed to numerous clinical trials, publications and presentations. Dr. Holdhoff serves as the director of the solid tumor inpatient service at the Sidney Kimmel Comprehensive Cancer Center. He is passionately involved in mentoring and teaching of fellows, residents and students. He is the director of the UCNS-certified neuro-oncology fellowship program at Johns Hopkins, and he is a teaching attending physician for the Osler internal medicine residency program. Dr. Holdhoff is rated as a Distinguished provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Glioma, Glioblastoma, Astrocytoma, and Brain Tumor.

Dr. Lode J. Swinnen is a cancer specialist in Baltimore caring for patients with lymphoma. Dr. Swinnen received his M.B.Ch.B. degree from the University of Cape Town Medical School. He completed his residency at Presence Saint Joseph Hospital and performed a fellowship in hematology-oncology at Loyola University Stritch School of Medicine. Dr. Swinnen joined the Johns Hopkins faculty in 2002. His research interests include lymphomas and immunodeficiency-associated malignancies. Dr. Swinnen is a member of the Eastern Cooperative Oncology Group and the National Comprehensive Cancer Network. Dr. Swinnen is rated as an Advanced provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Transplant.

Edward Lee, M.D. was named one of Baltimore’s “Top Doc’s” by Baltimore Magazine in 2000 and 2002. After receiving additional training in Hematology and Medical Oncology at the University of Maryland in 1984, he remained on faculty until 1997. During his academic career, Dr. Lee was chairman of the training program for five years, started the Bone Marrow Transplant Program at the University of Maryland in 1993, and wrote 50 original articles on leukemia, lymphoma and related diseases. In 1997, Dr. Lee entered private practice as Chief of Hematology and Medical Oncology at Sinai Hospital. Practicing in Columbia since 2001, Dr. Lee treats patients with all forms of cancer, maintaining a particular interest in breast cancer, leukemia, and lymphomas. Learn more at marylandoncology.com. Dr. Lee is rated as an Advanced provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Polycythemia Vera, Paget Disease of the Breast, Breast Cancer, and Primary Lymphoma of the Brain.

Dr. Nina Wagner-Johnston is Professor of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include non-Hodgkin lymphoma, Hodgkin lymphoma, and HIV-related lymphomas. Dr. Wagner-Johnston serves as the Director for the Lymphoma Drug Development Program at the Johns Hopkins University. Dr. Wagner-Johnston received her baccalaureate degree in nursing from Georgetown University in Washington, DC. She earned her MD and completed her residency training at the University of Chicago, Chicago Illinois. She performed a fellowship in Medical Oncology at Johns Hopkins University, Baltimore, Maryland. Dr. Wagner-Johnston joined the Johns Hopkins faculty in 2015. Prior to joining Johns Hopkins, Dr. Wagner-Johnston was an Assistant Professor at Washington University, St. Louis, Missouri. Her research interests include clinical trial and biomarker development for patients with lymphoma. She is additionally involved in palliative/supportive care research and has a particular interest in chemotherapy-induced peripheral neuropathy. Dr. Wagner-Johnston serves as a member on the NCCN Cancer Related Fatigue Guidelines Panel and the ASCO Neuropathy Guidelines Panel. She has served as a journal reviewer for Annals of Oncology, Leukemia and Lymphoma, Blood, and the Journal of Nuclear Medicine. She is a previous recipient of a Young Investigator Award at the Supportive Oncology Conference as well as a Mentoring Program Award through the American Academy of Hospice and Palliative Medicine. She has served on the National Cancer Institute (NCI) Lymphoma Steering Committee Clinical Trials Design Committee and the NCI Symptom Management and Health Related Quality of Life Steering Committee. She is a member of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the AIDS Malignancies Consortium (AMC), and the Eastern Cancer Oncology Group (ECOG) Lymphoma Committee. Dr. Wagner is rated as an Advanced provider by MediFind in the treatment of Primary Lymphoma of the Brain. Her top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Richard F. Ambinder, M.D., Ph.D., currently serves as the James B. Murphy Professor of Oncology and the Director of the Division of Hematologic Malignancies at the Johns Hopkins Kimmel Cancer Center. He is program co-leader of the Hematologic Malignancies and Bone Marrow Transplantation Program and leads the AIDS Malignancy Consortium (AMC) site at Johns Hopkins and the AMC Translational Sciences Working Group nationally. Dr. Ambinder graduated from Harvard College with a Bachelor’s degree in biochemistry, after which he received his medical degree from the Johns Hopkins University School of Medicine before completing his residency at the Johns Hopkins Hospital. He also earned his Ph.D. in pharmacology from the Johns Hopkins University, and completed his oncology fellowship at Johns Hopkins. Within the clinic, Dr. Ambinder is active in the treatment of lymphoma and Kaposi’s sarcoma. Dr. Ambinder’s research is focused on exploring opportunities to prevent or treat cancer with viral infections. Virus-associated tumors are among the most common malignancies in certain populations and regions. For instance, Burkitt's lymphoma (EBV) and Kaposi's sarcoma (KSHV) are common in equatorial Africa, nasopharyngeal carcinoma (EBV) is common in southern Chinese populations or those with southern Chinese origins, and immunoblastic lymphomas (EBV) are common in immunocompromised patients (organ transplant recipients, AIDS patients, etc). Thus, Dr. Ambinder’s new approaches to prevention, diagnosis, and treatment stand to have a direct impact on the lives of cancer patients around the globe. Additionally, the study of how viruses can impact these tumors is important in creating model systems for the development of new approaches to cancer care. Currently, many immunotherapies target unidentified antigens, making the measurement of relevant immune responses problematic at best. However, in EBV-associated tumors the antigens are well defined, thus allowing the Ambinder lab to define the epitope-specific cellular immune responses. As a result of this breakthrough, interventions designed to alter immune response —whether they be vaccine based interventions, adoptive immunotherapy interventions, or pharmacologic interventions — may all be assessed in terms of relevant surrogate markers. Much in the same way the treatment of Hodgkin's lymphoma with radiotherapy and chemotherapy paved the way for the modern approach to cancer treatment more broadly, the treatment of EBV-associated tumors (including Hodgkin's lymphoma) may pave the way to the more generalized use of these modalities to treat a myriad of cancer types. Dr. Ambinder is rated as an Advanced provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration.

Learn more at marylandoncology.com. Dr. Sastry is rated as an Advanced provider by MediFind in the treatment of Primary Lymphoma of the Brain. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Iron Deficiency Anemia, and Childhood Iron Deficiency Anemia.

Blanche Mavromatis is an Oncologist in Cumberland, Maryland. Dr. Mavromatis is rated as an Advanced provider by MediFind in the treatment of Primary Lymphoma of the Brain. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Chronic Lymphocytic Leukemia (CLL), and Richter Syndrome. Dr. Mavromatis is currently accepting new patients.

B.S., Massachusetts Institute of Technology M.D., University of Pennsylvania School of Medicine M.B.A., Carey School of Business at Johns Hopkins. Dr. Fuchs is rated as an Advanced provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Myelodysplastic Syndrome (MDS), Diffuse Large B-Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML), Multiple Myeloma, and Bone Marrow Aspiration.

Md Siddiqui is a Hematologist Oncology specialist and a Hematologist in Salisbury, Maryland. Dr. Siddiqui is rated as an Experienced provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Pulmonary Embolism, Inflammatory Breast Cancer, Angiosarcoma, and Childhood Iron Deficiency Anemia. Dr. Siddiqui is currently accepting new patients.

Myo Min is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Min is rated as a Distinguished provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Colorectal Cancer, and Large-Cell Immunoblastic Lymphoma. Dr. Min is currently accepting new patients.

Arun Bhandari, M.D. is a native of Maryland and grew up in Silver Spring area. He earned his medical degree from Punjabi University and Government Medical College, Punjab, India and completed his internship and residency in Internal Medicine at New York University program in Queens, NY. He completed his Hematology and Oncology fellowship at University of Tennessee Health Science Center, Memphis, TN, Georgetown University and Washington Hospital Center, Washington, DC and NHLBI at National Institute of Health, Bethesda, MD. He served as a chief fellow at Georgetown University and Washington Hospital Center, Washington, D.C. After completing his fellowship in 2005, he joined as faculty at Allegheny General Hospital in Pittsburgh, PA, where he was actively involved in teaching fellows and residents. He joined COHA in 2007 at which time he opened a location in Annapolis and Kent Island. He has interest in head and neck cancer, brain cancer, breast cancer, lung cancer, gastrointestinal cancer(colon, pancreas, liver, gastric, esophageal etc.), genitourinary cancer (kidney, prostate, bladder etc.), gynecological cancer (ovarian, uterine, cervical, vaginal etc.), skin cancer, Lymphoma, Myeloma, Leukemia and various other blood disorders. He is a member of the American Society of Clinical Oncology and American Society of Hematology. He currently sees patients at Annapolis Cancer Center and Kent Island Center. He speaks English, Hindi, and Punjabi. Dr. Bhandari is rated as an Experienced provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Pleuropulmonary Blastoma, Multiple Myeloma, Iron Deficiency Anemia, and Childhood Iron Deficiency Anemia.

Richard J. Jones, M.D., is a Professor of Oncology and Medicine, Director of the Bone Marrow Transplantation Program, and Co-Director of the Hematologic Malignancies Program at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Jones received his Bachelor of Science in chemistry from Bucknell University prior to completing his medical degree at the Temple University School of Medicine. He then completed his residency at Temple University Hospital, where he was appointed to serve as Chief Resident in Internal Medicine. Dr. Jones later came to Johns Hopkins to complete his Medical Oncology Fellowship, and was then recruited to the faculty. Dr. Jones’ research is aimed at better understanding the biology of normal and cancer stem cells, with the goal of translating promising findings to the clinic particularly in the area of blood and marrow transplantation (BMT). Dr. Jones' laboratory discovered one the most commonly-used stem cell markers, Aldefluor which identifies cells based on their expression of aldehyde dehydrogenase 1 (ALDH1), and have used this marker to identify and characterize normal stem cells and cancer stem cells from many hematologic malignancies. This work also led to the development of post-transplant cyclophosphamide and effective related haploidentical BMT. Cyclophosphamide is metabolized by ALDH1, which is the reason both stem cells and memory lymphocytes are resistant to the drug. Recently, Dr. Jones' laboratory found that cytochrome P450 enzymes are a major mechanism by which the bone marrow stem cell niche protects both normal and leukemia stem cells. Dr. Jones co-leads the Hematologic Malignancies and Bone Marrow Transplantation Research Program. In addition to his promising work in the laboratory, Dr. Jones is recognized as a gifted mentor. During his tenure at Hopkins, he has trained a generation of leading physician-scientists who have excelled at Johns Hopkins and across the country. Dr. Jones has also authored numerous peer-reviewed articles that have been published in such prestigious journals as Blood, Nature, the New England Journal of Medicine, Lancet, PNAS, the Annals of Internal Medicine, the Journal of Clinical Oncology, the Journal of the National Cancer Institute, the British Journal of Haematology, and Leukemia. Dr. Jones is rated as an Experienced provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma, Leukemia, and Splenectomy.

Dr. Chengcheng Gui is an instructor in the Department of Radiation Oncology and Molecular Radiation Sciences at the Johns Hopkins University School of Medicine. His clinical focus is the use of radiotherapy to treat head and neck cancers, as well as skin cancers. Dr. Gui obtained his medical degree from the Johns Hopkins University School of Medicine and completed his residency training at Memorial Sloan Kettering Cancer Center, where he served as chief resident and received the Radiation Oncology Medical Student Teaching Award. Dr. Gui believes that cancer patients deserve a clear and thorough understanding of the benefits and risks of their treatment options, empowering them to choose the path that best aligns with their personal values. To support this, Dr. Gui is committed to being an approachable, trustworthy source of information, while also planning and delivering high-quality radiotherapy. Research Summary Dr. Gui's research focuses on enhancing the safety and effectiveness of radiotherapy by integrating multiple data modalities. His work incorporates advanced structural and functional imaging, tumor molecular characteristics, and patient-reported outcomes to inform and personalize treatment approaches. Selected Publications Gui C, Wray R, Schöder H, Deasy JO, Grkovski M, Humm JL, Wong RJ, Sherman EJ, Riaz N, Lee NY. Tumor hypoxia on 18F-fluoromisonidazole positron emission tomography and distant metastasis from head and neck squamous cell carcinoma. JAMA Network Open. 2024 Sep 3;7(9):e2436407-. Gui C, Walch H, Mueller K, Boe L, Skakodub A, Miao E, Khatri I, Kumar R, Padilla Mazzeo, Shen J, Cooper C, Parker M, Hsu A, Patel R, Ilica AT, Stember JN, Eichholz JE, Bou Nassif R, Yu KKH, Wilcox JA, Manca P, Yu Y, Yamada Y, Imber BS, Maron SB, Foote MB, Chatila WK, Yaeger R, Schultz N, Pike LRG. Genomics correlates of brain metastasis and progression in colorectal cancer. Neuro-Oncology. 2025 Aug 28:noaf198. doi: 10.1093/neuonc/noaf198. Online ahead of print. Gui C, Vannorsdall TD, Kleinberg LR, Assadi R, Moore JA, Hu C, Quiñones-Hinojosa A, Redmond KJ. A prospective cohort study of neural progenitor cell-sparing radiation therapy plus temozolomide for newly diagnosed patients with glioblastoma. Neurosurgery. 2020 Jul 1;87(1):E31-40. Redmond KJ, Gui C, Benedict S, Milano MT, Grimm J, Vargo JA, Soltys SG, Yorke E, Jackson A, El Naqa I, Marks LB. Tumor control probability of radiosurgery and fractionated stereotactic radiosurgery for brain metastases. International Journal of Radiation Oncology* Biology* Physics. 2021 May 1;110(1):53-67. Eitz KA, Lo SS, Soliman H, Sahgal A, Theriault A, Pinkham MB, Foote MC, Song AJ, Shi W, Redmond KJ, Gui C, Kumar AMS, Machtay M, Meyer B, Combs SE. Multi-institutional analysis of prognostic factors and outcomes after hypofractionated stereotactic radiotherapy to the resection cavity in patients with brain metastases. JAMA Oncology. 2020 Dec 1;6(12):1901-9. Dr. Gui is rated as an Experienced provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Brain Tumor, Primary Lymphoma of the Brain, Myxoid Liposarcoma, Endoscopy, and Osteotomy.

Dr. Jaishri Blakeley is the Marjorie Bloomberg Tiven Professor of Neurofibromatosis in Neurology, Oncology, and Neurosurgery at Johns Hopkins School of Medicine, director of the Johns Hopkins Comprehensive Neurofibromatosis Center and director of the Neurofibromatosis Therapeutic Acceleration Program (NTAP). She is an active clinician-scientist specializing in the care of people with NF1, NF2, LZTR1, SMARC1 schwannomatoses, and primary brain tumors. Her research expertise in the development of clinical trials for nervous system tumors and specifically, early clinical-translational studies including tumor pharmacokinetic and pharmacodynamic investigations, imaging biomarkers for rare nervous system tumors, and incorporation of patient-focused, functional endpoints into efficacy studies. She has been the national or international leader of 7 clinical trials focused on therapies for glioblastoma, NF1 and NF2. In 2012 she cofounded the NTAP to dramatically shift the landscape of NF1 via necessary, efficient, and expert discovery, translational and clinical research. NTAP focuses on therapeutics, fosters collaboration, facilitates open and timely sharing of results, and streamlines the research process to accelerate therapies for plexiform and cutaneous neurofibromas. Through NTAP, Dr. Blakeley has supported and collaborated with more than 80 laboratories and research teams across the globe enabling meaningful therapeutic development for NF1-associated neoplasms and supporting the development of an exceptional community of clinician scientists focused on NF1 via the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research. Her research and programmatic efforts are all in the service of improving outcomes for the patients with NF1, NF2, schwannomatosis, and primary brain cancer for whom she is honored to provide care. Dr. Blakeley is rated as an Experienced provider by MediFind in the treatment of Primary Lymphoma of the Brain. Her top areas of expertise are Neurofibromatosis, Schwannomatosis, Neurofibromatosis Type 2 (NF2), Neurofibromatosis Type 1 (NF1), and Laminectomy.

Andrew Mener, M.D. has experience treating a wide range of adult hematologic and oncologic disorders, with a particular interest in treating breast, lung, gastrointestinal and hematologic malignancies. He takes great pride in delivering personalized, compassionate care and strives to effectively explain complex treatment options to his patients. He strongly believes in the importance of treating each and every patient as an individual. Learn more at marylandoncology.com. Dr. Mener is rated as an Experienced provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Iron Deficiency Anemia, and Severe Congenital Neutropenia.

William Houck is an Oncologist in Baltimore, Maryland. Dr. Houck is rated as an Experienced provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Paget Disease of the Breast, Lung Cancer, Chronic B-Cell Leukemia (CBCL), and Chronic Lymphocytic Leukemia (CLL).

"Shannon C. O'Connor, M.D., is a medical oncologist with Suburban Hospital. She practices out of Maryland Oncology Hematology. Dr. O'Connor has expertise in hematology and medical oncology with a special focus in women's health, including breast cancer and gynecologic cancers. Dr. O'Connor earned her Master's Degree in Physiology at Georgetown University, followed by her medical degree from St. George's University School of Medicine. She completed a residency at Washington Hospital Center, as well as a fellowship in hematology and oncology. Dr. O'Connor is a member of the American Society of Clinical Oncology, the American Society of Hematology, the Montgomery County Medical Society and the American Medical Association. Selected Publications Catlett JP1, Williams SA, O'Connor SC, Krishnan J, Malkovska V. ""Primary lymphoma of bone: an institutional experience."" Leuk Lymphoma. 2008 Nov;49(11):2125-32. doi: 10.1080/10428190802404030.". Dr. O'connor is rated as an Experienced provider by MediFind in the treatment of Primary Lymphoma of the Brain. Her top areas of expertise are Paget Disease of the Breast, Cervical Cancer, Neuroendocrine Carcinoma of the Cervix, and Breast Cancer.

As an active participant in the medical community, Mohit Narang, M.D. has served as a primary investigator and research assistant on many trials. During Dr. Narang’s fellowship, he was honored with the invitation to attend the Masterclass in Clinical Oncology at Montecatini, Italy by the European School of Oncology. He holds professional memberships with the American Society of Clinical Oncology, American Society of Hematology, as well as the European Society of Medical Oncology. Learn more at marylandoncology.com. Dr. Narang is rated as an Experienced provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Multiple Myeloma, Agranulocytosis, Paget Disease of the Breast, Thrombocytopenia, and Bone Marrow Transplant.

"Dr. Fariba Asrari is the director of Johns Hopkins Breast Center at Green Spring Station. She received her medical degree with honors from Shiraz Medical School in Iran and completed Internal medicine residency training at affiliated Hospitals of University of Pennsylvania in Philadelphia. She then completed her second residency training in Radiation Oncology at Hahnemann university in Philadelphia. She is an active member of the American Society for Therapeutic Radiology and Oncology as well as the American Medical Association, American Radium Society, Mid-Atlantic Society of Radiation Oncologists and American Society of Clinical Oncology. She is the treasurer of Mid-Atlantic Society of Radiation Oncologists. Dr. Asrari's special interest is in breast and gynecologic malignancies as well as skin cancer. She also participates in resident and medical student teaching. She is the recipient of 2006 Director's Teaching Award in Clinical Science at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and 2006 ""Teacher of The Year Award"" of Association of Residents in Radiation Oncology. She also has received 2005 Thomas Fercoit Memorial Professional of The Year Award from ""The ARC of Baltimore"" in appreciation of her dedicated care of individuals with developmental disabilities. Make A Gift". Dr. Asrari is rated as an Experienced provider by MediFind in the treatment of Primary Lymphoma of the Brain. Her top areas of expertise are Breast Cancer, Prostate Cancer, Merkel Cell Carcinoma, and Angiosarcoma.

As an Associate Professor and Director of the Gastrointestinal Program in the Department of Radiation Oncology and Molecular Radiation Sciences at the Johns Hopkins School of Medicine, Dr. Meyer's clinical and research focus is on the treatment of gastrointestinal cancers, including rectal, anal, esophageal, pancreatic, and liver malignancies. He is also leading the effort to establish a liver stereotactic body radiation therapy (SBRT) program within the department. Dr. Meyer has experience with clinical research studies in SBRT, as well as radiation and drug combination therapy for cancer. Make A Gift. Dr. Meyer is rated as an Experienced provider by MediFind in the treatment of Primary Lymphoma of the Brain. His top areas of expertise are Anal Cancer, Cholangiocarcinoma (Bile Duct Cancer), Familial Pancreatic Cancer, and Pancreatic Cancer.